Abstract:Approximately 70% of patients diagnosed with non-small cell lung cancer (NSCLC) are not eligible for curative resection, often due to disseminated disease at diagnosis. Thus, the advent of novel therapeutics, especially those efficacious for metastatic disease, is of primary importance. Metastasis correlates with epigenetic alterations that drive tumor plasticity and adaptive heterogeneity in response to the multiple microenvironments metastatic cells see, yet the molecular mechanisms underlying these epigenetic alterations remain poorly understood. We performed a functional genomic screen and identified the lysine 36 on histone H3 (H3K36) demethylase KDM2A as a mediator of in vivo and in vitro metastatic competence in multiple models of NSCLC. KDM2A depletion in highly metastatic NSCLC cell lines reduces their capacity to form multi-tumor cell clusters. In vivo, KDM2A depletion does not impact lung orthotopic tumor cell growth or the total number of circulating tumor cells (CTCs) but does reduce their ability to colonize distant metastatic sites. This is consistent with the fact that human CTCs found in clusters are more metastatic than CTCs which disseminate as single-cells. Because the molecular and biological consequences of H3K36 regulation are context dependent, we performed for the first time an integrated transcriptomic-epigenomic analysis of target gene regulation, KDM2A genomic binding, H3K36 methylation, and H3K27 acetylation, in metastatic cell clusters. KDM2A enhances the expression of cell adhesion and anti-oxidant genes, while suppressing inflammatory gene responses, and this regulation preferentially occurs in tumor cell clusters. Transcriptomic analysis of CTCs from patients confirms that KDM2A regulated transcriptional responses correlate with metastatic relapse across multiple cancer types. Moreover, KDM2A may function both as a transcriptional activator and repressor in metastatic clusters. As KDM2A encodes for several domains which can independently regulate E3-ubiqutin ligation, H3K36me2 demethylation, and DNA methylation, we have also performed a structure function analysis of K2MDA in the context of metastatic phenotypes. Thus, the distinct biochemical functions of KDM2A in relation to its regulation of CTC gene transcription and histone modification will also be presented. In conclusion, we have identified KDM2A as a novel regulator of NSCLC metastatic spread. The ability to inhibit KDM2A with small molecule inhibitors may be translated into effective therapeutic interventions for NSCLC patients with metastasis disease. Citation Format: Carolyn Kravitz, Kiran D. Patel, Wesley L. Cai, Anna Arnal-Estapé, Dejian Zhao, Emily Wingrove, Laura Stevens, Thomas F. Westbrook, Qin Yan, Don X. Nguyen. The lysine demethylase KDM2A regulates tumor cell clustering to potentiate metastasis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1718.

KDM1A promotes tumor cell invasion by silencing TIMP3 in non-small cell lung cancer cells

KDM 1 A Promotes Tumor Cell Invasion by Silencing TIMP 3 in Non-Small Cell Lung Cancer Cells

KDM1A, a potent and selective target, for the treatment of DNMT3A-deficient non-small cell lung cancer

Histone 3 Lysine-27 Demethylase KDM6A Coordinates with KMT2B to Play an Oncogenic Role in NSCLC by Regulating H3K4me3

TET1 Suppresses Cancer Invasion by Activating the Tissue Inhibitors of Metalloproteinases.

Knockdown of KDM1A Suppresses Tumour Migration and Invasion by Epigenetically Regulating the TIMP1/MMP9 Pathway in Papillary Thyroid Cancer.

Kdm2a Promotes Lung Tumorigenesis by Epigenetically Enhancing Erk1/2 Signaling

KDM1A and KDM3A promote tumor growth by upregulating cell cycle-associated genes in pancreatic cancer

Abstract 1718: The lysine demethylase KDM2A regulates tumor cell clustering to potentiate metastasis

METTL3 promotes the malignancy of non-small cell lung cancer by N6-methyladenosine modifying SFRP2

Overexpression of DNMT1 Accelerates Migration and Invasion of Lung Squamous Cell Carcinoma Cells by Decreasing TCF21 Expression Via the Akt/p65 Signaling Pathway

Loss of Kmt2c or Kmt2d drives brain metastasis via KDM6A-dependent upregulation of MMP3

KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming

Histone Demethylase KDM3A Promotes Cervical Cancer Malignancy Through the ETS1/KIF14/Hedgehog Axis.

KDM3B-ETF1 fusion gene downregulates LMO2 via the WNT/β-catenin signaling pathway, promoting metastasis of invasive ductal carcinoma

Tumor-derived exosomal miR-3157-3p promotes angiogenesis, vascular permeability and metastasis by targeting TIMP/KLF2 in non-small cell lung cancer

KDM6A Promotes Angiogenesis, Migration, and Invasion of Pancreatic Cancer by Activating LAMP3

KIAA1199 promotes invasion and migration in non-small-cell lung cancer (NSCLC) via PI3K-Akt mediated EMT

FKBP51 promotes invasion and migration by increasing the autophagic degradation of TIMP3 in clear cell renal cell carcinoma

Lysine-specific demethylase 5C promotes hepatocellular carcinoma cell invasion through inhibition BMP7 expression

Dynamin 3 Inhibits the Proliferation of Non-small-Cell Lung Cancer Cells by Suppressing c-MET–GBR2–STAT3 Complex Formation